---
title: "JACOBSON PHARMA and Jianbei Miao Miao: Europharma and Europharma (Hong Kong) entered into a 2025 licensing agreement with Europharma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263062654.md"
description: "JACOBSON PHARMA and Jianbei Miao Miao announced the signing of a licensing agreement with Europharma (Hong Kong) for 2025, allowing the use of certain factories, with a term from December 1, 2025, to January 27, 2028, and a monthly licensing fee of HKD 247,000. This agreement will bring rental income to Europharma and provide manufacturing space for Europharma (Hong Kong), avoiding high relocation costs"
datetime: "2025-10-28T10:48:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263062654.md)
  - [en](https://longbridge.com/en/news/263062654.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263062654.md)
---

# JACOBSON PHARMA and Jianbei Miao Miao: Europharma and Europharma (Hong Kong) entered into a 2025 licensing agreement with Europharma

According to the Zhitong Finance APP, JACOBSON PHARMA (02633) and Jianbei Miao Miao (02161) jointly announced that due to the expiration of the licensing agreement in 2020 on November 30, 2025, Europharma and Europharma (Hong Kong) entered into the 2025 Europharma Licensing Agreement on October 28, 2025. Europharma agreed to license Europharma (Hong Kong) to use part of the factory according to the terms and conditions of the 2025 Europharma Licensing Agreement, with a term from December 1, 2025, to January 27, 2028 (including the first and last days), with a monthly licensing fee of HKD 247,000.

It is reported that Europharma Limited is a wholly-owned subsidiary of JACOBSON. Europharma (Hong Kong) Limited is a wholly-owned subsidiary of Jianbei Miao Miao.

Since 2007, Europharma has leased a factory in the Science Park for the manufacture of pharmaceuticals. According to the lease, Europharma may license certain entities to use the factory with prior written approval from the Science Park.

This licensing arrangement under the 2025 Europharma Licensing Agreement brings rental income from unused factory space to Europharma and provides Europharma (Hong Kong) with suitable manufacturing facilities. Relocating Europharma (Hong Kong)'s existing facilities that comply with pharmaceutical production quality management standards is costly and time-consuming. Therefore, the 2025 Europharma Licensing Agreement allows Europharma (Hong Kong) to operate without interruption and avoid relocation expenses

### Related Stocks

- [02633.HK](https://longbridge.com/en/quote/02633.HK.md)

## Related News & Research

- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [Tencent Music completes $2.6 billion acquisition of podcast platform Ximalaya](https://longbridge.com/en/news/286841981.md)
- [Dunkin' To Give Away 1 Mln Free Coffees For A Day](https://longbridge.com/en/news/286964019.md)
- [20:38 ETHyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"](https://longbridge.com/en/news/287135394.md)
- [Investment giants join forces to form largest healthcare firm on the globe](https://longbridge.com/en/news/287091936.md)